Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
DVA · NYSE · Healthcare
Fundamental quality
55
out of 100
Davita Inc. earns a fundamental-quality score of 55 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its financial strength (net debt 3.53× EBITDA). Its weakest area is its profitability (net margin 6%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
DaVita is one of America's two big dialysis networks: thousands of clinics where hundreds of thousands of kidney patients get treated three times a week, for life. A duopoly of inelastic demand and captive customers, with Berkshire Hathaway as a longtime shareholder.
EPS growth: 12.6% · Revenue growth: 3.6%
Net margin: 6% · ROIC: 18.3%
Net debt/EBITDA: 3.53x · FCF: 11.5%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 11,551 | 774 | 1,304 | 7,592 |
| 2021 | 11,619 | 978 | 1,289 | 8,267 |
| 2022 | 11,610 | 560 | 961 | 8,449 |
| 2023 | 12,140 | 692 | 1,491 | 7,888 |
| 2024 | 12,816 | 936 | 1,467 | 8,381 |
| 2025 | 13,643 | 747 | 1,311 | 9,488 |
Between 2020 and 2025, revenue went from $11,551M to $13,643M (+18%) and net income went from $774M to $747M (-3%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Davita Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Davita Inc. a good company to invest in?
In terms of business quality, Davita Inc. scores 55 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Davita Inc. a profitable company?
Davita Inc. is profitable, with a net margin of 6%, though a thin one.
Does Davita Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.53 times its EBITDA.
Is Davita Inc. growing?
Its revenue has grown 3.6% annualized in recent years and its earnings per share 12.6%.
Does Davita Inc. generate cash?
Yes. It converts about 11.5% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Insulet (PODD) · Edwards Lifesciences (EW) · Molina Healthcare (MOH) · Medline (MDLN) · Tenet Healthcare (THC) · Universal Health Services (UHS) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Davita Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.